Company Overview and News

2
Caeneus Minerals is the ASX Most Active at noon, King River Copper not far behind

2018-06-04 proactiveinvestors.com.au
Caeneus Minerals Ltd (ASX:CAD) is the most active stock on the ASX intra-day, having traded 29 million shares by noon, although these high volumes are due to a share price of 0.1 cents.
CAD KRC PAB VML

2
Caeneus Minerals is the ASX Most Active at noon, King River Copper Ltd not far behind

2018-06-04 proactiveinvestors.com.au
Caeneus Minerals Ltd (ASX:CAD) is the most active stock on the ASX intra-day, having traded 29 million shares by noon, although these high volumes are due to a share price of 0.1 cents.
CAD KRC PAB VML

0
Vital Metals reveals positive cobalt results from sampling in Germany

2018-05-15 proactiveinvestors.com.au
Vital Metals Limited (ASX:VML) has received 0.8% cobalt and 1.3% nickel results from rock samples taken from the historical Stolln 7 uranium exploration waste dump at the Aue Project in Germany.
VML

0
Vital Metals to sell QLD tungsten project for $15m in cash

2018-05-02 australianmining.com.au
Explorer Vital Metals has signed a binding term sheet to sell its Queensland-based Watershed tungsten project to Tungsten Mining for $15 million in cash.
TGN VML

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:VML / VITAL METALS LIMITED on message board site Silicon Investor.

VSM MedTech Ltd - VML.A